The company’s Q4FY21 revenue rose to 47% yoy to Rs454cr compared to Rs308.9cr in Q4FY20. FY21 revenue was up 22% yoy (30% ex Ranitidine) at 1,645.7cr compared to Rs1,349.3cr in FY20.
EBITDA in March ended fourth quarter stood at Rs105cr, up 74% yoy from Rs60.5cr in Q4FY20. EBITDA for fiscal FY21 was up 43% yoy at Rs400.4cr compared to Rs279.3cr in FY20. Basic EPS was at Rs15.57 in Q4FY21, and at Rs69.00 in FY21.
The company Board recommends a final dividend of 30% (Rs3/- per share), leading to a total dividend for the year of 70% (Rs7/- per share).
“Solara’s excellent execution and strong customer partnerships have powered us to a record annual performance. We have delivered exceptional YoY growth on all key financial metrics. The drive and passion of our employees have anchored Solara as a partner of choice with our customers.
We continue to grow our business in both regulated and other markets leading to a balanced market footprint. I am very proud to share that our cost improvement programs continue to deliver superior results. I am confident that the Solara efficiency machine will maintain this momentum in the future,” said, Bharath Sesha, the MD & CEO of the company.
Sesha further added, “Our strategy execution has gained traction with the announced merger of Solara and Aurore. It is EPS accretive immediately for Solara shareholders. We are very excited about the synergies this combination will generate.
The merger adds momentum to our CRAM s growth, bolsters our presence in focus markets, enhances our product portfolio and boosts R&D velocity. While we retain a strong position on base products, we will scale up high margin new products and our CRAM s business, leading to continued growth momentum for Solara.”
Solara Active Pharma Sciences Ltd trade on Thursday ended at Rs1,640.85 per piece up by Rs30.05 or 1.87% from its previous closing of Rs1,610.80 per piece on the BSE.